Drug Profile
Glycine/lysine acetylsalicylate inhalation - Ventaleon
Alternative Names: Acti-INSP-001; Glycine/lysine acetylsalicylate inhalation - Vectura; LASAG; Lysine acetylsalicylate glycine inhalation - Vectura; Lysine acetylsalicylate/glycine inhalation - Vectura; VR 736Latest Information Update: 29 Jul 2016
Price :
$50
*
At a glance
- Originator Activaero GmbH
- Developer Vectura; Ventaleon
- Class Antiplatelets; Antipyretics; Antirheumatics; Antivirals; Basic amino acids; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Salicylates; Small molecules
- Mechanism of Action Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Influenza virus infections
Most Recent Events
- 29 Jul 2016 Glycine/lysine acetylsalicylate inhalation is still in phase II trials in Influenza virus infections (in hospitalised patients) (Vectura pipeline, July 2016)
- 13 Mar 2014 Activaero GmbH has been acquired by Vectura
- 12 Feb 2013 Phase-II clinical trials in Influenza virus infections (in hospitalised patients) in Latvia, Lithuania and Spain (Inhalation)